Leerink Partners analyst Mani Foroohar has reiterated their bearish stance on MRNA stock, giving a Sell rating on November 14.Don't Miss our ...

Friday was a doozy for many biotech and pharmaceutical companies after news broke late Thursday that President-elect Donald Trump would nominate vaccine skeptic Robert F. Kennedy Jr. to the nation's ...

Moderna plans to prioritize new product approvals and oncology investments, as political concerns over Robert F. Kennedy Jr.'s HHS nomination weigh on vaccine stocks.

Shares in biotech firm Moderna (NASDAQ:MRNA) rose more than 4% Monday after HSBC raised its rating on the stock from Hold to Buy while trimming the target price to $58 from $82.

Kennedy Jr. to head the U.S. Department of Health and Human Services makes a good entry point for investors, according to Piper Sandler. Piper Sandler, which reiterated Overweight rating on Moderna, ...

For young, healthy people who may be wondering, “do I need a COVID booster at all?”, having one annually is sensible.

(Reuters) -Shares in European vaccine makers fell on Friday after U.S. President-elect Donald Trump picked Robert F. Kennedy ...

Donald Trump has delivered a blow to the drug makers he claims hampered his 2020 election bid with the appointment of vaccine ...

Pfizer's stock dropped 4.3 percent while Moderna's fell 3.1 percent and Novavax saw a 2.8 percent dip in its stock Friday ...

( NewsNation) — Shares in some pharmaceutical and biotechnology companies, including those that manufacture vaccines, fell ...

If you missed the early fall push for flu and COVID-19 vaccines, it’s not too late. Health officials say it’s important to ...

The S&P 500 sank 1.1 per cent and was heading for a losing week and its worst day since October. The Dow Jones Industrial ...